7 years later, are the Tomlinson’s levodopa dose equivalencies proposed consensual?
Objective: (i) To collect all the levodopa equivalent doses (LED) formulae and references used in clinical trials in Parkinson’s disease (PD) since the publication of…Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic
Objective: The objective of this open-label study was to evaluate the clinical utility of the Personal KinetiGraph™ (PKG) Movement Recording System in the care of…Weight variation in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion
Objective: To compare weight variations between three cohorts of patients with advanced Parkinson’s disease (PD): patients during their first year of treatment either with levodopa-carbidopa…Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy
Objective: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than 7 million people worldwide. However, treatment outcome in many patients…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…Association between serum Vitamin D levels and Parkinson’s disease: A systematic review and meta-analysis
Objective: The aim of this systematic review and meta-analysis was to evaluate the association between serum vitamin D levels and the risk and severity of…Effect of dopamine agonists versus levodopa as initial treatment in Parkinson’s Disease
Objective: We evaluated the efficacy of different starting drugs in the treatment of Parkinson's disease (PD), in order to further explore the initial therapy of…Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project
Objective: Our objective was to develop and pilot test a scale (OPTIPARK) for assessing a patient´s dopaminergic state, allowing the clinician to consider the adjustment…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia
Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 34
- Next Page »